QQQ   443.97 (-0.19%)
AAPL   171.41 (-1.10%)
MSFT   420.72 (-0.17%)
META   485.90 (-1.61%)
GOOGL   150.80 (-0.05%)
AMZN   180.38 (+0.31%)
TSLA   175.79 (-2.25%)
NVDA   903.56 (+0.12%)
NIO   4.50 (-3.64%)
AMD   180.49 (+0.50%)
BABA   72.36 (+1.08%)
T   17.60 (+0.28%)
F   13.28 (+1.68%)
MU   117.89 (-1.05%)
CGC   8.63 (-9.63%)
GE   175.53 (-2.55%)
DIS   122.36 (+1.14%)
AMC   3.72 (-14.29%)
PFE   27.75 (-0.11%)
PYPL   66.99 (+0.63%)
XOM   116.24 (+1.10%)
QQQ   443.97 (-0.19%)
AAPL   171.41 (-1.10%)
MSFT   420.72 (-0.17%)
META   485.90 (-1.61%)
GOOGL   150.80 (-0.05%)
AMZN   180.38 (+0.31%)
TSLA   175.79 (-2.25%)
NVDA   903.56 (+0.12%)
NIO   4.50 (-3.64%)
AMD   180.49 (+0.50%)
BABA   72.36 (+1.08%)
T   17.60 (+0.28%)
F   13.28 (+1.68%)
MU   117.89 (-1.05%)
CGC   8.63 (-9.63%)
GE   175.53 (-2.55%)
DIS   122.36 (+1.14%)
AMC   3.72 (-14.29%)
PFE   27.75 (-0.11%)
PYPL   66.99 (+0.63%)
XOM   116.24 (+1.10%)
QQQ   443.97 (-0.19%)
AAPL   171.41 (-1.10%)
MSFT   420.72 (-0.17%)
META   485.90 (-1.61%)
GOOGL   150.80 (-0.05%)
AMZN   180.38 (+0.31%)
TSLA   175.79 (-2.25%)
NVDA   903.56 (+0.12%)
NIO   4.50 (-3.64%)
AMD   180.49 (+0.50%)
BABA   72.36 (+1.08%)
T   17.60 (+0.28%)
F   13.28 (+1.68%)
MU   117.89 (-1.05%)
CGC   8.63 (-9.63%)
GE   175.53 (-2.55%)
DIS   122.36 (+1.14%)
AMC   3.72 (-14.29%)
PFE   27.75 (-0.11%)
PYPL   66.99 (+0.63%)
XOM   116.24 (+1.10%)
QQQ   443.97 (-0.19%)
AAPL   171.41 (-1.10%)
MSFT   420.72 (-0.17%)
META   485.90 (-1.61%)
GOOGL   150.80 (-0.05%)
AMZN   180.38 (+0.31%)
TSLA   175.79 (-2.25%)
NVDA   903.56 (+0.12%)
NIO   4.50 (-3.64%)
AMD   180.49 (+0.50%)
BABA   72.36 (+1.08%)
T   17.60 (+0.28%)
F   13.28 (+1.68%)
MU   117.89 (-1.05%)
CGC   8.63 (-9.63%)
GE   175.53 (-2.55%)
DIS   122.36 (+1.14%)
AMC   3.72 (-14.29%)
PFE   27.75 (-0.11%)
PYPL   66.99 (+0.63%)
XOM   116.24 (+1.10%)
NASDAQ:OTLK

Outlook Therapeutics (OTLK) Stock Price, News & Analysis

$11.94
+2.57 (+27.43%)
(As of 04:00 PM ET)
Today's Range
$9.36
$12.70
50-Day Range
$5.73
$9.70
52-Week Range
$4.00
$40.60
Volume
1.54 million shs
Average Volume
563,410 shs
Market Capitalization
$155.34 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$46.43

Outlook Therapeutics MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.88 Rating Score
Upside/​Downside
289.8% Upside
$46.43 Price Target
Short Interest
Healthy
10.61% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.83mentions of Outlook Therapeutics in the last 14 days
Based on 26 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($2.99) to ($1.84) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.51 out of 5 stars

Medical Sector

338th out of 938 stocks

Biological Products, Except Diagnostic Industry

49th out of 154 stocks

OTLK stock logo

About Outlook Therapeutics Stock (NASDAQ:OTLK)

Outlook Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has collaboration and license agreements with BioLexis Pte. Ltd. and Zhejiang Huahai Pharmaceutical Co., Ltd. The company was formerly known as Oncobiologics, Inc. and changed its name to Outlook Therapeutics, Inc. in November 2018. Outlook Therapeutics, Inc. was incorporated in 2010 and is based in Iselin, New Jersey.

OTLK Stock Price History

OTLK Stock News Headlines

A lot of people are making this costly mistake
You may have heard the saying “options are risky” … And, they can be. But only if you use them the way a lot of folks do. A lot of people think of BUYING speculative options when they talk about options. And BUYING low probability, speculative options is definitely risky… It’s how some folks leverage large sums of money hoping that a stock moves in the “right” direction over a certain period of time.
AI to Meet the Same Fate as EVs?
When these tech bubbles burst, they invariably leave investors disillusioned by their losses. Now, many worry a similar fate is awaiting AI. And one man, legendary financial analyst Porter Stansberry, who called Nvidia at $11…
EQS-News: Management Board Gives Positive Outlook for FY 2023/2024
Outlook Therapeutics Inc (41ON.MU)
See More Headlines
Receive OTLK Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Outlook Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/14/2024
Today
3/28/2024
Next Earnings (Estimated)
5/20/2024
Fiscal Year End
9/30/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
N/A
Current Symbol
NASDAQ:OTLK
Fax
N/A
Employees
24
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$46.43
High Stock Price Target
$100.00
Low Stock Price Target
$20.00
Potential Upside/Downside
+299.9%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.88
Research Coverage
8 Analysts

Profitability

Net Income
$-58,980,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
($1.11) per share

Miscellaneous

Free Float
12,323,000
Market Cap
$151.05 million
Optionable
Not Optionable
Beta
N/A
These 7 Stocks Will Be Magnificent in 2024 Cover

With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.

Get This Free Report

Key Executives


OTLK Stock Analysis - Frequently Asked Questions

Should I buy or sell Outlook Therapeutics stock right now?

8 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Outlook Therapeutics in the last twelve months. There are currently 1 hold rating and 7 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" OTLK shares.
View OTLK analyst ratings
or view top-rated stocks.

What is Outlook Therapeutics' stock price target for 2024?

8 Wall Street analysts have issued 1 year price objectives for Outlook Therapeutics' stock. Their OTLK share price targets range from $20.00 to $100.00. On average, they predict the company's share price to reach $46.43 in the next twelve months. This suggests a possible upside of 289.8% from the stock's current price.
View analysts price targets for OTLK
or view top-rated stocks among Wall Street analysts.

How have OTLK shares performed in 2024?

Outlook Therapeutics' stock was trading at $7.88 at the beginning of the year. Since then, OTLK stock has increased by 51.1% and is now trading at $11.91.
View the best growth stocks for 2024 here
.

Are investors shorting Outlook Therapeutics?

Outlook Therapeutics saw a decrease in short interest in the month of March. As of March 15th, there was short interest totaling 785,300 shares, a decrease of 93.3% from the February 29th total of 11,640,000 shares. Based on an average trading volume of 496,200 shares, the short-interest ratio is presently 1.6 days. Approximately 10.6% of the company's stock are short sold.
View Outlook Therapeutics' Short Interest
.

When is Outlook Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, May 20th 2024.
View our OTLK earnings forecast
.

How were Outlook Therapeutics' earnings last quarter?

Outlook Therapeutics, Inc. (NASDAQ:OTLK) announced its earnings results on Wednesday, February, 14th. The company reported ($0.80) earnings per share for the quarter, beating analysts' consensus estimates of ($1.00) by $0.20.

When did Outlook Therapeutics' stock split?

Outlook Therapeutics shares reverse split on the morning of Thursday, March 14th 2024. The 1-20 reverse split was announced on Thursday, March 14th 2024. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, March 14th 2024. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

What other stocks do shareholders of Outlook Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Outlook Therapeutics investors own include Matinas BioPharma (MTNB), KushCo (KSHB), Bionano Genomics (BNGO), SCYNEXIS (SCYX), Gran Tierra Energy (GTE), ADMA Biologics (ADMA), Zosano Pharma (ZSAN), Novan (NOVN), Organigram (OGI) and CNBX Pharmaceuticals (CNBX).

Who are Outlook Therapeutics' major shareholders?

Outlook Therapeutics' stock is owned by many different institutional and retail investors. Top institutional investors include Vanguard Group Inc. (2.52%), Vanguard Group Inc. (2.52%), Northern Trust Corp (0.53%), Scotia Capital Inc. (0.11%), Barclays PLC (0.08%) and BNP Paribas Financial Markets (0.03%). Insiders that own company stock include C Russell Trenary III, Ghiath M Sukhtian, Jeff Evanson, Kurt J Hilzinger, Terry Dagnon and Yezan Munther Haddadin.
View institutional ownership trends
.

How do I buy shares of Outlook Therapeutics?

Shares of OTLK stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:OTLK) was last updated on 3/28/2024 by MarketBeat.com Staff

From Our Partners